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vealed that once internalized, CEA- nal. In this light, FAS is likely to be ex- resistant state. In this case, finding ways
pressed at levels far greater than those of to mimic the inhibitory effects of the tyro-CAM1 can bind to FAS, in the process
CEACAM1. Moreover, the requirement for sine phosphorylated peptide might help tolowering FAS activity (Figure 1). The
internalization of CEACAM1 in endocy- alleviate chronically elevated plasma andbinding and inhibition were absolutely
totic vesicles to exert its inhibitory action hepatic lipidemia in diabetes.dependent on tyrosine phosphorylation
on FAS makes the feat even more difficult.of CEACAM1, thus explaining the effect
Thus, the fraction of FAS that undergoes Alan R. Saltielof insulin. In support of the model, dis-
catalytic inhibition by CEACAM1 needs to Life Sciences Instituteruption of the CEACAM1 gene or trans-
be clarified, as does the molecular mech- University of Michigangenic expression of a phosphorylation-
anism(s) by which this tyrosine phosphor- Ann Arbor, Michigan 48109deficient mutant in liver prevents the
ylated transmembrane protein interactsacute inhibitory effect of insulin and re- Selected readingwith FAS and blocks its catalytic activity.sults in elevated hepatic lipogenesis. In-
The specific blockade of FAS activity Najjar, S.M. (2002). Trends Endocrinol. Metab.terestingly, since the expression of CEA-
by CEACAM1 in liver may provide a clue 13, 240–245.CAM1 is liver specific, this effect of
to understanding so-called “mixed insu- Najjar, S., Yang, Y., Fernström, M.A., Lee, S.-J.,insulin is not seen in adipose tissue,
lin resistance” that has been observed Abou-Rjaily, G.A., DeAngelis, A.M., Al-Share,where lipogenesis is increased by insulin
in a number of models of obesity and Q.Y., Miller, T.A., Dai, T., Ratnam, S., et al. (2005).
in both the acute and chronic phases. Cell Metab. 2, this issue, 43–53.lipodystrophy (Shimomura et al., 2000).
The study raises a number of impor- In this scenario, insulin’s antigluconeoge- Saltiel, A.R., and Kahn, C.R. (2001). Nature 414,tant questions, most of which focus on 799–806.nic and glycogenic actions are compro-
the mechanism of CEACAM1’s inhibitory mised, whereas its lipogenic effects re- Shimomura, I., Matsuda, M., Hammmer, R.E.,actions on FAS. The first and most obvi- main intact, and fat accumulates in the Bashakov, Y., Brown, M.S., and Goldstein, J.L.
ous pertains to the stoichiometry of the (2000). Mol. Cell 6, 77–86.liver. Although mutations in CEACAM1
interaction between these proteins. Since have not been found in patients with di- Zammit, V.A. (2002). Ann. N Y Acad. Sci. 967,
CEACAM1 is a relatively immobile trans- abetes or insulin resistance, it is tempt- 52–65.
membrane protein that co-segregates ing to speculate that CEACAM1-depen-
DOI 10.1016/j.cmet.2005.06.010with the insulin receptor, its tyrosine dent inhibition of fatty acid synthesis
phosphorylation would not lead to sig might be compromised as a conse-
quence or even a cause of the insulin-nificant amplification of the insulin sig-Lipid links to better bone: A hyPOThesis
The combined resorptive activity of osteoclasts and the bone-generating function of osteoblasts result in the constant
renewal of this vital tissue. It has long been appreciated that the coupled degradation and formation of bone is coordi-
nately regulated by a complex interplay between endocrine and paracrine effectors; a recent report by Idris et al. (2005)
now documents the possibility that cannabinoid receptors may also impact bone mass.The diverse roles of cannabinoids in nu- p
merous aspects of neurophysiology have o
wrecently been brought to light, starting
with the identification of 9 tetrahydro- t
wcannabinol (THC) as the active ingredient
of cannabis and the cloning thereafter of
tthe cannabinoid receptors (CBs) 1 and 2
(reviewed in Howlett et al., 2004). Endoge- t
βnous ligands for CB1 and CB2, which are
members of the superfamily of seven a
atransmembraneG-coupled receptors, were
isolated from brain and identified as ar- t
pachidonoylethanolamine (anandamine)
and 2-arachidonoyl glycerol, putatively t
pspecific for CB1 and CB2, respectively.
Given the considerable interest in the a2sychopharmacology and potential uses i
mf THC, in particular those associated
ith addiction, specific agonists and an- d
bagonists have been developed, some of
hich are in clinical trials. e
iIt has become increasingly obvious in
he last few years that bone mass is con- c
brolled by the nervous system, through
-adrenergic receptors in its sympathetic m
srm and several hypothalamic hormones
cting centrally (Zaidi, 2005). Based on s
fhese observations, Idris et al. (2005) pro-
osed that yet-other neuroactive recep- e
mors/ligands may contribute to bone
hysiology. To test this hypothesis, they c
Issessed the bone status of mice lack-ng CB1 and their wild-type (wt) litter-
ates. The data show that bone mineral
ensity is higher at the spine and in long
ones of null mice and that these differ-
nces are not accounted for by changes
n osteoblast or osteoclast number. Of
onsiderable interest, while wt mice lose
one rapidly following ovariectomy, a
odel for postmenopausal osteoporo-
is, mice lacking CB1 are spared. A
eries of in vitro studies were next per-
ormed to identify the cells responsive to
ndogenous cannabinoids. Treatment of
urine osteoblast cultures with CB-spe-
ific ligands failed to alter cell number.
n contrast, both CB1 and CB2 antago-CELL METABOLISM : JULY 2005
P R E V I E Wnists inhibited osteoclast formation from s
myeloid precursors dose dependently, l
while anandamide and a synthetic ago- a
nist increased the number of bone- t
resorbing cells. Furthermore, the endog- t
enous lipid reversed the inhibitory effect C
of a CB1 antagonist, suggesting target o
receptor specificity. These data indicate n
that osteoclasts and/or their precursors t
may be direct targets of endogenous can- c
nabinoids, and the presence of CB1 and w
CB2 on mouse osteoclasts, as shown t
cby immunohistochemistry and Western
blot analysis, confirmed this possibility. m
wIn further studies, osteoclast precur-n
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tFigure 1. Potential cannabinoid signaling pathways in osteoclasts
hOsteoclasts derive from myeloid precursors under the influence of M-CSF and RANKL. Binding of these
rcytokines to their receptors stimulates the ERK, PI3K/Akt, JNK, and NFκB pathways, with subsequent activa-
tion of a range of transcription factors, as well as signals that enhance cell survival and cytoskeletal reorgani- o
zation. Additionally, RANKL increases intracellular Ca2+, which acts through the calcium-dependent phospha- (
tase calcineurin to facilitate nuclear translocation of NFAT1c (solid black lines). Cannabinoids have been breported to stimulate many of the same pathways (dashed blue lines and red boxes), one or more of which
rmay thus mediate their impact on osteoclast formation and/or function. PM = plasma membrane.
w
o
cCELL METABOLISM : JULY 2005nors isolated from wt mice or animals
tacking CB1 were treated with M-CSF
and RANKL, which are standard condi-
ions for in vitro osteoclastogenesis, in
ahe presence or absence of CB1- and
tB2-specific antagonists. As predicted,
ssteoclast formation was unchanged in
aull mice treated with the former inhibi-
sor. Unexpectedly, given the claimed re-
aeptor specificity, the second molecule
has similarly potent. In vivo confirmation
ohat both receptors play a role in osteo-
last function was provided by experi- a
rents in which mice lacking ovaries
ere injected with CB1 and CB2 antago- sists. In both instances the compounds
rotected against bone loss at dosages
onsistent with their efficacy in other sys-
ems. Thus, both in vitro and in vivo find-
ngs suggest that CB1 and CB2 are in-
olved in the regulation of bone resorption
y inhibiting osteoclast function.
Since osteoclasts are terminally dif-
erentiated cells that undergo apoptosis
ollowing withdrawal of or exposure to
pecific cytokines or drugs, the authors
lso asked if CB1 and/or CB2 antago-
ists could stimulate cell death and in-
eed found enhanced levels of TUNEL
taining and cleaved caspase 3, a down-
tream executioner of apoptosis (Danial
nd Korsmeyer, 2004). Turning to the
ignaling pathways mediating these
vents, the authors determined that the
nhibitors blocked RANKL-induced acti-
ation of the ERK pathway and the DNA
inding capacity of c-Fos, c-jun, and
FAT1c, three transcription factors whose
uclear transcription and activation par-
llel osteoclast formation and function
Boyle et al., 2003).
These studies expand our horizons on
he interactions between endogenous
annabinoids and bone biology and sug-
est a model that might integrate our
resent knowledge and the current find-
ngs (Figure 1). Nevertheless, a number
f important questions remain unan-
wered. Immune cells express CB2, and
here are reports that monocytes/macro-
hages also bear this family of recep-
or(s) (Howlett et al., 2004). On the other
and, little is known about ligand(s) or
eceptor(s) in the context of bone biol-
gy. Thus, two important questions are
1) what are the endogenous canna-
inoids present in the bone micro-envi-
onment; are they regulated, and if so,
hat are the mechanisms? (2) do levels
f CB1 and/or CB2 alter during osteo-
last differentiation, as is the case for a
umber of membrane-residing proteins
hat modulate the osteoclast (Teitelbaum
nd Ross, 2003)?
Since the authors propose that ERKs
re an important signal for CB signal
ransduction, it might have been in-
tructive to treat the cells with an avail-
ble specific MEK inhibitor. Moreover,
ince M-CSF strongly stimulates ERK
ctivation, the former cytokine might
ave been used as the agonist in place
f RANKL. Furthermore, the increased
poptosis seen in osteoclasts is not
eadily explained on the basis of ERK
ignaling. Alternatively, several pathways3
P R E V I E Wdownstream of RANK and/or c-Fms, the c
oreceptors for RANKL and M-CSF, re-
tspectively, influence osteoclast survival
(Figure 1). Thus, activation of the PI3K/
FAkt axis by genetic deletion of the 5#
Dpoly-inositol phosphatase SHIP1 in-
creases osteoclast life span 3-fold (Ta-
Wkeshita et al., 2002). Similarly, both the
NFκB and JNK pathways have major ef-
Cfects on cell viability (Papa et al., 2004).
6Finally, RANKL-induced increases in in-
Stracellular calcium activate the phospha-
tase calcineurin, facilitating nuclear trans-
location of NFAT1c (Boyle et al., 2003). S
In sum, this interesting manuscript re-
Bveals that bone cells are, directly or indi-
Brectly, targets for lipids; a recently docu- d
mented example of the latter is the v
interesting report linking lysophospha- B
tidic acid, platelets, and osteoclasts (
(Boucharaba et al., 2004). Given the
D
plethora of lipid-regulated signals (Mool- 1
enaar et al., 2004; Newton, 2004; Parker,
H
2004; Spiegel and Milstein, 2003), it a
bshould be no surprise if future studies4monfirm the hypothesis that many classes
Wf lipids have important and new roles
5
o play in bone biology.
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